Predictive value of C-reactive protein combined with triglyceride glucose index for coronary heart disease risk in patients with rheumatoid arthritis

doi:10.3969/j.issn.1004-583X.2024.06.004

Abstract

Abstract:

Objective To explore the predictive value of C-reactive protein (CRP) and triglyceride glucose (TyG) index for coronary heart disease (CHD) risk in patients with rheumatoid arthritis. Methods Totally 300 eligible patients diagnosed with RA admitted to the Department of Rheumatology and Immunology of the Affiliated Hospital of Jining Medical University from January 2019 to December 2022 were included and screened. The subjects were divided into CHD group (102 cases) and non-CHD group (198 cases) based on the performance of CHD or not. The baseline information and laboratory data were collected. After analyzing their differences, statistically significant indicators were included in logistic regression analysis, a regression model was built to observe the correlation between CRP and TyG index with the risk of CHD in RA patients, and receiver operating characteristic (ROC) curves of CRP, TyG index and CRP combined with TyG index were plotted. Area under the curve (AUC) was reported to evaluate the predictive value of CRP and TyG index for CHD in RA patients. Results Correlation analysis showed that CRP, fasting blood glucose (FBG), TyG index, age, history of hypertension and history of diabetes were significantly different between the two groups. Logistic regression analysis showed that CRP, TyG index, history of hypertension and age were independent risk factors for CHD in RA patients. The AUC of CRP, TyG index and their combined coefficient was 0.608, 0.602 and 0.656, respectively. Conclusion The combination of CRP and TyG index has good predictive value for the risk of CHD in RA patients.

Key words: arthritis, rheumatoid, coronary disease, C-reactive protein, triglyceride-glucose index

CLC Number:

R593.22

Song Yijing, Li Jian, Song Qin, Shao Li. Predictive value of C-reactive protein combined with triglyceride glucose index for coronary heart disease risk in patients with rheumatoid arthritis[J]. Clinical Focus, 2024, 39(6): 506-511.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2024.06.004

https://huicui.hebmu.edu.cn/EN/Y2024/V39/I6/506

Figures/Tables 7

References 28

[1]	Wang Z, Lan T, Zhang L, et al. Predictive value of the TyG index and rheumatoid factor for cardiovascular disease risk in a rheumatoid arthritis population: Data from a survey of 418 patients[J]. Lipids Health Dis, 2022, 21(1):122. doi: 10.1186/s12944-022-01735-6 pmid: 36397103
[2]	Contreras-Haro B, Hernandez-Gonzalez SO, Gonzalez-Lopez L, et al. Fasting triglycerides and glucose index: A useful screening test for assessing insulin resistance in patients diagnosed with rheumatoid arthritis and systemic lupus erythematosus[J]. Diabetol Metab Syndr, 2019, 11:95. doi: 10.1186/s13098-019-0495-x pmid: 31788032
[3]	Zhao J, Fan H, Wang T, et al. TyG index is positively associated with risk of CHD and coronary atherosclerosis severity among NAFLD patients[J]. Cardiovasc Diabetol, 2022, 21(1):123. doi: 10.1186/s12933-022-01548-y pmid: 35778734
[4]	Wang Z, Hu K, Wu M, et al. Factors associated with secondary coronary artery disease in rheumatoid arthritis patients: A systematic review and meta-analysis based on observational studies[J]. Musculoskeletal Care, 2023.
[5]	Quevedo-Abeledo JC, Rúa-Figueroa Í, Sánchez-Pérez H, et al. Comparable effects of traditional cardiovascular risk factors on subclinical atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis[J]. Clin Exp Rheumatol, 2020, 38(5):917-924. pmid: 31969232
[6]	England BR, Thiele GM, Anderson DR, et al. Increased cardiovascular risk in rheumatoid arthritis: Mechanisms and implications[J]. BMJ, 2018, 361:k1036.
[7]	Lee TH, Song GG, Choi SJ, et al. Relationship of rheumatoid arthritis and coronary artery disease in the Korean population: A nationwide cross-sectional study[J]. Adv Rheumatol, 2019, 59(1):40. doi: 10.1186/s42358-019-0084-6 pmid: 31455419
[8]	Wang H, Li X, Gong G. Cardiovascular outcomes in patients with co-existing coronary artery disease and rheumatoid arthritis: A systematic review and meta-analysis[J]. Medicine (Baltimore), 2020, 99(14):e19658.
[9]	Sengul I, Akcay-Yalbuzdag S, Ince B, et al. Comparison of the DAS28-CRP and DAS28-ESR in patients with rheumatoid arthritis[J]. Int J Rheum Dis, 2015, 18(6):640-645. doi: 10.1111/1756-185X.12695 pmid: 26013310
[10]	Hannawi S, Hannawi H, Al SI. Cardiovascular disease and subclinical atherosclerosis in rheumatoid arthritis[J]. Hypertens Res, 2020, 43(9):982-984. doi: 10.1038/s41440-020-0483-4 pmid: 32483312
[11]	Pope JE, Choy EH. C-reactive protein and implications in rheumatoid arthritis and associated comorbidities[J]. Semin Arthritis Rheum, 2021, 51(1):219-229.
[12]	Xu J, Xu W, Chen G, et al. Association of TyG index with prehypertension or hypertension: A retrospective study in Japanese normoglycemia subjects[J]. Front Endocrinol (Lausanne), 2023, 14:1288693.
[13]	Jian S, Su-Mei N, Xue C, et al. Association and interaction between triglyceride-glucose index and obesity on risk of hypertension in middle-aged and elderly adults[J]. Clin Exp Hypertens, 2017, 39(8):732-739.
[14]	Huang Z, Ding X, Yue Q, et al. Triglyceride-glucose index trajectory and stroke incidence in patients with hypertension: A prospective cohort study[J]. Cardiovasc Diabetol, 2022, 21(1):141. doi: 10.1186/s12933-022-01577-7 pmid: 35897017
[15]	Peng N, Kuang M, Peng Y, et al. Associations between TyG-BMI and normal-high blood pressure values and hypertension: Cross-sectional evidence from a non-diabetic population[J]. Front Cardiovasc Med, 2023, 10:1129112.
[16]	Zheng R, Mao Y. Triglyceride and glucose (TyG) index as a predictor of incident hypertension: A 9-year longitudinal population-based study[J]. Lipids Health Dis, 2017, 16(1):175. doi: 10.1186/s12944-017-0562-y pmid: 28903774
[17]	Elazab SA, Elsayed WE, Alrahim NM, et al. Relationship between triglyceride-glucose index and disease activity and subclinical atherosclerosis in rheumatoid arthritis[J]. Curr Rheumatol Rev, 2023.
[18]	Wang A, Tian X, Zuo Y, et al. Change in triglyceride-glucose index predicts the risk of cardiovascular disease in the general population: A prospective cohort study[J]. Cardiovasc Diabetol, 2021, 20(1):113. doi: 10.1186/s12933-021-01305-7 pmid: 34039351
[19]	Liang S, Wang C, Zhang J, et al. Triglyceride-glucose index and coronary artery disease: A systematic review and meta-analysis of risk, severity, and prognosis[J]. Cardiovasc Diabetol, 2023, 22(1):170. doi: 10.1186/s12933-023-01906-4 pmid: 37415168
[20]	Tian X, Zuo Y, Chen S, et al. Distinct triglyceride-glucose trajectories are associated with different risks of incident cardiovascular disease in normal-weight adults[J]. Am Heart J, 2022, 248:63-71. doi: 10.1016/j.ahj.2022.02.014 pmid: 35248535
[21]	Che B, Zhong C, Zhang R, et al. Triglyceride-glucose index and triglyceride to high-density lipoprotein cholesterol ratio as potential cardiovascular disease risk factors: an analysis of UK biobank data[J]. Cardiovasc Diabetol, 2023, 22(1):34. doi: 10.1186/s12933-023-01762-2 pmid: 36797706
[22]	Muhammad IF, Bao X, Nilsson PM, et al. Triglyceride-glucose (TyG) index is a predictor of arterial stiffness, incidence of diabetes, cardiovascular disease, and all-cause and cardiovascular mortality: A longitudinal two-cohort analysis[J]. Front Cardiovasc Med, 2022, 9:1035105.
[23]	Fan J, Gao ST, Wang LJ, et al. Association of three simple insulin resistance indexes with prehypertension in normoglycemic subjects[J]. Metab Syndr Relat Disord, 2019, 17(7):374-379. doi: 10.1089/met.2019.0029 pmid: 31211636
[24]	Yu H, Tao L, Li YG, et al. Association between triglyceride-glucose index trajectories and carotid atherosclerosis progression[J]. Cardiovasc Diabetol, 2023, 22(1):130. doi: 10.1186/s12933-023-01847-y pmid: 37254140
[25]	Zhang F, Zhang Y, Guo Z, et al. The association of triglyceride and glucose index, and triglyceride to high-density lipoprotein cholesterol ratio with prehypertension and hypertension in normoglycemic subjects: A large cross-sectional population study[J]. J Clin Hypertens (Greenwich), 2021, 23(7):1405-1412. doi: 10.1111/jch.14305 pmid: 34118112
[26]	Wang X, Xu W, Song Q, et al. Association between the triglyceride-glucose index and severity of coronary artery disease[J]. Cardiovasc Diabetol, 2022, 21(1):168. doi: 10.1186/s12933-022-01606-5 pmid: 36050734
[27]	Wang J, Huang X, Fu C, et al. Association between triglyceride glucose index, coronary artery calcification and multivessel coronary disease in Chinese patients with acute coronary syndrome[J]. Cardiovasc Diabetol, 2022, 21(1):187. doi: 10.1186/s12933-022-01615-4 pmid: 36114495
[28]	Karpouzas GA, Ormseth SR, Hernandez E, et al. The impact of statins on coronary atherosclerosis progression and long-term cardiovascular disease risk in rheumatoid arthritis[J]. Rheumatology (Oxford), 2022, 61(5):1857-1866.

组别	例数		性别[例(%)]			吸烟史[例(%)]				年龄 (岁)		BMI (kg/m²)
组别	例数		男		女	有		无		年龄 (岁)		BMI (kg/m²)
非CHD组	198		67(33.8)		131(66.2)	49(24.7)		149(75.3)		57.98±11.16		22.41(20.55, 24.97)
CHD组	102		26(25.5)		76(74.5)	26(25.5)		76(74.5)		68.26±8.73		23.71(20.59, 26.51)
统计值			χ²=2.193			χ²=0.020				t=8.760		Z=-1.606
P值			0.139			0.888				<0.01		0.108
组别		饮酒史[例(%)]					高血压史[例(%)]				糖尿病史[例(%)]
组别		有		无			有		无		有		无
非CHD组		39(19.7)		159(80.3)			37(18.7)		161(81.3)		14(7.1)		184(92.9)
CHD组		15(14.7)		87(85.3)			53(52.0)		49(48.0)		24(23.5)		78(76.5)
统计值		χ²=1.136					χ²=35.492				χ²=16.485
P值		0.286					<0.01				<0.01

组别	例数		性别[例(%)]			吸烟史[例(%)]				年龄 (岁)		BMI (kg/m²)
组别	例数		男		女	有		无		年龄 (岁)		BMI (kg/m²)
非CHD组	198		67(33.8)		131(66.2)	49(24.7)		149(75.3)		57.98±11.16		22.41(20.55, 24.97)
CHD组	102		26(25.5)		76(74.5)	26(25.5)		76(74.5)		68.26±8.73		23.71(20.59, 26.51)
统计值			χ²=2.193			χ²=0.020				t=8.760		Z=-1.606
P值			0.139			0.888				<0.01		0.108
组别		饮酒史[例(%)]					高血压史[例(%)]				糖尿病史[例(%)]
组别		有		无			有		无		有		无
非CHD组		39(19.7)		159(80.3)			37(18.7)		161(81.3)		14(7.1)		184(92.9)
CHD组		15(14.7)		87(85.3)			53(52.0)		49(48.0)		24(23.5)		78(76.5)
统计值		χ²=1.136					χ²=35.492				χ²=16.485
P值		0.286					<0.01				<0.01

组别	例数	CRP(mg/L)		ESR(mm/H)	RF(IU/ml)		TG(mmol/L)		TC(mmol/L)
非CHD组	198	18.35(5.50, 45.16)		55.00(27.50, 84.00)	120.50(44.95, 230.25)		0.90(0.70,1.23)		3.92(3.41,4.48)
CHD组	102	33.64(11.30, 72.70)		50.50(29.00, 87.25)	146.60(51.53, 293.38)		0.95(0.71,1.46)		3.95(3.21,4.68)
统计值		Z=-3.050		Z=-0.474	Z=-1.231		Z=-1.614		Z=-0.414
P值		0.002		0.636	0.128		0.106		0.679
组别	HDL-C(mmol/L)		LDL-C(mmol/L)			FBG(mg/dL)		TyG指数
非CHD组	1.08(0.92, 1.29)		2.35(1.97, 2.91)			88.30(81.09, 101.63)		8.20(7.94, 8.49)
CHD组	1.15(0.95, 1.31)		2.42(1.83, 2.81)			99.11(84.69, 117.13)		8.37(7.99, 8.82)
统计值	Z=-1.175		Z=-0.525			Z=-3.304		Z=-2.895
P值	0.240		0.599			<0.01		0.004

组别	例数	CRP(mg/L)		ESR(mm/H)	RF(IU/ml)		TG(mmol/L)		TC(mmol/L)
非CHD组	198	18.35(5.50, 45.16)		55.00(27.50, 84.00)	120.50(44.95, 230.25)		0.90(0.70,1.23)		3.92(3.41,4.48)
CHD组	102	33.64(11.30, 72.70)		50.50(29.00, 87.25)	146.60(51.53, 293.38)		0.95(0.71,1.46)		3.95(3.21,4.68)
统计值		Z=-3.050		Z=-0.474	Z=-1.231		Z=-1.614		Z=-0.414
P值		0.002		0.636	0.128		0.106		0.679
组别	HDL-C(mmol/L)		LDL-C(mmol/L)			FBG(mg/dL)		TyG指数
非CHD组	1.08(0.92, 1.29)		2.35(1.97, 2.91)			88.30(81.09, 101.63)		8.20(7.94, 8.49)
CHD组	1.15(0.95, 1.31)		2.42(1.83, 2.81)			99.11(84.69, 117.13)		8.37(7.99, 8.82)
统计值	Z=-1.175		Z=-0.525			Z=-3.304		Z=-2.895
P值	0.240		0.599			<0.01		0.004

因素	回归系数	标准误	Wald χ²值	P值	OR值	95%CI
因素	回归系数	标准误	Wald χ²值	P值	OR值	下限	上限
高血压史(有/无)	0.867	0.306	8.051	0.005	2.380	1.308	4.333
糖尿病史(有/无)	0.614	0.445	1.906	0.167	1.847	0.773	4.415
CRP(mg/L)	0.009	0.004	5.526	0.019	1.009	1.001	1.016
FBG(mg/dL)	0.001	0.007	0.038	0.846	1.001	0.988	1.015
TyG指数	0.827	0.363	5.178	0.023	2.286	1.122	4.660
年龄(岁)	0.087	0.016	29.144	<0.01	1.091	1.057	1.126
常量	-13.966	3.284	18.085	<0.01	0.000